Gyre Therapeutics falls on downbeat annual revenue outlook

Gyre Therapeutics

12/03/2026 11:20

** Shares of biotech firm Gyre Therapeutics GYRE.O fall 6.72% to $7.77 premarket

** Co expects FY26 revenue in the range of $100.5 million to $111 million, below analysts' estimate of $148 million, according to data compiled by LSEG

** Co says it expects 2026 to be a transition period with focus on regulatory activities

** Plans to submit a marketing application in China for conditional approval of Hydronidone, its liver fibrosis drug candidate, in 1H 2026

** GYRE expects to moderate promotional activities for its newer drugs Contiva and Etorel, amid procurement uncertainties in China

** Posts Q4 revenue of $37.2 million vs analysts' estimate of $35.4 million

** GYRE shares were down over 41% in 2025

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))